Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories |
|
| 2 | Active Comparator | Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories | Drug |
| ||
| Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence based on AUC and Cmax | 33 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| A. Orson Brod, M.D. | PharmaKineticsLaboratories, Inc | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C004704 | cyclobenzaprine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|